Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

Lilly and Almac partner on companion diagnostic for lung cancer
October 2009
SHARING OPTIONS:

  BELFASTóLilly UK and Almac Diagnostics, a personalized medicine company providing translational genomic-based solutions for pharma, biotech and academic customers, have partnered on the development of a companion diagnostic for Lilly's Alimta, with cisplatin, as a combination therapy for non-squamous, non-small cell lung cancer. Almac's technical team will perform global gene expression profiling, microRNA profiling, SNP genotyping, qPCR validation, data analysis and project management of the study. The final endpoint will be the development of a companion diagnostic test that will select patients likely to benefit from treatment with Alimta. Financial terms of the partnership were not released.

 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.